Iluvien (Fluocinolone Acetonide)

• Iluvien is a corticosteroid implant used to manage ocular conditions characterized by chronic inflammation and fluid accumulation.
• Diabetic macular edema (center‑involved): reduces retinal swelling and improves visual acuity.
• Diabetic macular edema (persistent after anti‑VEGF therapy): provides sustained anti‑inflammatory control.
• Chronic non‑infectious posterior uveitis: controls intra‑ocular inflammation and limits macular edema.

• Fluocinolone acetonide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses the synthesis of pro‑inflammatory cytokines and prostaglandins, decreases vascular permeability, and stabilises the blood‑retinal barrier, thereby reducing ocular edema and inflammation.

Iluvien may be associated with ocular adverse reactions that vary in frequency and severity.

Common Side Effects

• Increased intraocular pressure: may require topical pressure‑lowering therapy.
• Cataract formation: accelerated progression in phakic eyes.
• Vitreous floaters: transient visual disturbances after implantation.
• Ocular discomfort or pain: typically mild and self‑limiting.
• Conjunctival hemorrhage: small bleed at injection site.
• Reduced visual acuity: temporary changes during the early post‑implant period.

Serious or Rare Side Effects

• Endophthalmitis: severe intra‑ocular infection requiring urgent treatment.
• Retinal detachment: rare but vision‑threatening complication.
• Implant migration: movement of the device to an unintended intra‑ocular location.
• Severe ocular hypertension: may need surgical intervention.
• Uveitis flare: paradoxical inflammation in susceptible patients.
• Optic nerve damage: extremely rare, associated with uncontrolled pressure.

Prior to Iluvien implantation, clinicians should evaluate ocular health and systemic factors.

• Monitor intraocular pressure: schedule regular tonometry assessments.
• Assess cataract status: inform phakic patients of potential lens opacification.
• Avoid in active ocular infection: postpone implantation until infection resolves.
• Use caution in glaucoma patients: heightened risk of pressure spikes.
• Counsel on need for long‑term ophthalmic follow‑up: detect late‑onset effects.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct light.

Iluvien may interact with other ocular or systemic therapies that influence steroid exposure or intra‑ocular pressure.

Major Interactions (Avoid)

• Systemic corticosteroids: additive systemic glucocorticoid effects.
• Concurrent intra‑ocular steroids: increased risk of ocular hypertension.
• Strong CYP3A4 inhibitors: potential elevation of intra‑ocular fluocinolone levels.

Moderate Interactions (Monitor Closely)

• Topical non‑steroidal anti‑inflammatory drugs: may raise risk of corneal complications.
• Anticoagulants: heightened bleeding risk during injection procedure.
• Glaucoma medications: may require dose adjustment if intra‑ocular pressure rises.
• Anti‑VEGF agents administered within 4 weeks: monitor for overlapping inflammation control.